ストックスクリーナーアプリを入手
2.99
2.61%
-0.08
前日終値:
$3.07
開ける：
$3.14
24時間の取引高:
371.97K
Relative Volume:
0.88
時価総額：
$99.33M
収益：
$66.16M
当期純損益:
$128.94M
株価収益率:
0.9396
EPS:
3.1823
ネットキャッシュフロー:
$152.08M
1週間 パフォーマンス:
+8.33%
1か月 パフォーマンス:
+20.56%
6か月 パフォーマンス:
-9.94%
1年 パフォーマンス:
+65.19%
1日の値動き範囲:
$2.98
$3.1595
1週間の範囲:
$2.73
$3.1595
52週間の値動き範囲:
$1.70
$4.53
Fortress Biotech Inc Stock (FBIO) Company Profile
名前
Fortress Biotech Inc
セクター
電話
781-652-4500
住所
1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY
Compare FBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FBIO
Fortress Biotech Inc
|
2.99 | 99.33M | 66.16M | 128.94M | 152.08M | 3.1823 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-15 | 再開されました | ROTH MKM | Buy |
| 2022-08-04 | 開始されました | Ladenburg Thalmann | Buy |
| 2020-10-02 | 開始されました | The Benchmark Company | Buy |
| 2019-12-18 | 開始されました | B. Riley FBR | Buy |
| 2018-02-28 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-07-11 | 開始されました | Rodman & Renshaw | Buy |
| 2017-03-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-10-03 | 開始されました | ROTH Capital | Buy |
すべてを表示
Fortress Biotech Inc (FBIO) 最新ニュース
Fortress Biotech Inc (FBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fortress Biotech Inc (FBIO) Institutional Confidence - TradingKey
Fortress Biotech Inc (FBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fortress Biotech Inc (FBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fortress Biotech Inc (FBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mustang Bio Inc (MBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fortress Biotech (FBIO) AGM 2026 Summary - Quartr
Fortress Biotech Inc (FBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fortress Biotech Inc (FBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fortress Biotech Inc (FBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fortress Biotech Inc. Q4 2025 Earnings: EPS Misses Estimates, Stock Rises Amid Strategic UpdateCFO Commentary Report - newsline.com
(FBIOP) Volatility Zones as Tactical Triggers - Stock Traders Daily
FBIOP Q4 2025 Earnings: Preferred Stock Reports Wider-than-Expected Loss Amid Narrowing Pipeline Progress - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Edges Higher Before Resistance TestPut Support - newsline.com
Why Is Fortress Biotech Stock Falling Today? - MSN
FBIOP Q4 2025 Earnings: Preferred Stock Faces EPS Miss as Company Reports LossEPS Revision Trend - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Faces Resistance, Slides 2.3% in Quiet SessionProtective Put - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Pulls Back 2.3% as Shares Approach Key SupportDescending Triangle - newsline.com
Price-Driven Insight from (FBIOP) for Rule-Based Strategy - Stock Traders Daily
Fortress Biotech Inc stock (US32015L1035): Nasdaq-listed biotech moves in low-volume trade ahead of - AD HOC NEWS
Fortress Biotech Preferred Stock (FBIOP) Surges 5.19%, Nears Key Resistance at $21.5BPI Bear Confirmed - newsline.com
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO) - Seeking Alpha
FBIO Q4 2025 Earnings: EPS Misses Estimates, Stock Moves HigherEarnings Quality Analysis - newsline.com
FBIO Q4 2025 Earnings: EPS Misses Estimates as Revenue Remains AbsentEarnings Seasonality - The Legal Advocate
Fortress Biotech Preferred (FBIOP) Rises 2.37%; Support and Resistance in FocusSynthetic Long - The Legal Advocate
Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise By Investing.com - Investing.com South Africa
Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise - Investing.com Canada
FBIOP Q4 2025 Earnings: Preferred Stock Reports Negative EPS Surprise Amid No Revenue Disclosure - newsline.com
Fortress Biotech Preferred Shares (FBIOP) Advance 2.45% as Support Holds Near $16Dark Pool Prints - The Legal Advocate
FBIO Q4 2025 Earnings: Deep EPS Miss Highlights Challenges for Pre-Revenue BiotechTrough Earnings Signal - Newser
(FBIOP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Fortress Biotech Preferred Stock (FBIOP) Q4 2025 Earnings: EPS Misses Estimates by Over 108%Community Sell Signals - Newser
Fortress Biotech (FBIO) Gains 1.62% as Shares Approach Key Resistance at $2.97Stock Analysis - Newser
Fortress Biotech Inc. (FBIO) Moves Higher as Buyers Defend Key Support LevelLarge Cap Trends - The Legal Advocate
FBIO Q4 2025 Earnings: Significant EPS Surprise Miss Amid Limited Revenue DisclosureOne-Time Loss Impact - newsline.com
Fortress Biotech (FBIO) Q4 2025 Results Miss Estimates — EPS $-0.01 vs $0.11Consensus Beat Rate - Newser
FBIOP Stock Price, Quote & Chart | FORTRESS BIOTECH INCFBIO 9 3/8 PERP (NASDAQ:FBIOP) - ChartMill
Fortress Biotech (FBIO) Q4 2025 Earnings: Miss Sparks ConcernGAAP Earnings Report - Newser
Fortress Biotech (FBIO) Q4 2025 Miss: What Went WrongInterim Report - Newser
Journey Medical CEO to join online talk at A.G.P. health event - Stock Titan
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference - Sahm
A. G. P. Maintains Fortress Biotech(FBIO.US) With Buy Rating, Raises Target Price to $5 - Moomoo
Why Fortress Biotech (FBIO) Just Surged +5.81% — Key Levels Ahead 2026-05-18Factor Timing - Newser
FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease - Stocktwits
Number of shareholders of Fortress Biotech, Inc. – NASDAQ:FBIO - TradingView
Fortress Biotech, Inc.9.375% Series A Cumulative Redeemable Perpetual Preferred Stock - TradingView
Fortress Biotech stock (US32015L1035): FDA setback hits Menkes drug while investors eye next catalys - AD HOC NEWS
Fortress Biotech Inc at Planet MicroCap Showcase Virtual Investor Conference 2020 Transcript - GuruFocus
Highbridge (FBIO) reports 2.73M warrant-backed shares, 7.8% stake - Stock Titan
FBIOP | Fortress Biotech, Inc. 9.375% Insider Trading - Quiver Quantitative
Fortress Biotech Inc (FBIO) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):